alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### *In the Matter of*Nan Mickel, *a Negro Girl.*

ALBANY,

August, 1817.

The owner of a slave, by his will, dated the 15th *January,*3813, declared as follows: “ I *Manumit*and give freedom to any negro woman *Mott,*and her daughter *Man,*immedidecíase.” The viards,sold *Nan*and died:’ *Beid*that the sale of the slave, by revóSoBoníi* she *wa^aot‘enfteldom'0 after Ills decease. To render a factual, there certificate,8°or vered°’by the slave, or to son for his'be-some third person for his benefit, so as to actofTnumtes,Dn‘-

THIS case came before the court upon the return to a *Habeas Corpus,*directed to *Samuel M'Clallen,*who held, and claimed, a negro girl, named *Nan Mickel,*as his slave.

*Henry Michael,*the owner of the negro girl, by his last will and testament, dated the 15th day of *January,*1813, declared as follows: “ I manumit and give freedom to my negro woman *Molt,*and her daughter *Nan,*immediately after my decease.’’ The testator, however, soon after the date of his will, sold *Nan*as a slave to one *Cook,*from whom *M‘Clallan*derived his title.

The testator, *Michael,*afterwards died. The question submitte<^ to the consideration of the court, by the consent of parties, on the facts above stated, was, whether, under these circumstances, the negro girl *Nan*was entitled to her freedom ?

*Per Curiam.*

The sale made by, the testator, after making his will was, *pro tanto,*a revocation of the will. This would certainly be the operation as to the disposition of any other property owned by him, and there can be no solid reason why it should not be so with respect to this wench. It ought to be observed, that she is not claimed as a slave for life,but only until she is 25 year's of age, having been born since *July,*1799. A will has no effect, or operation, until the death of the testator. No person can claim any right, or interest, under it. It is completely under the control and direction of the testator. Although a manumission of a slave does not rest upon the principles of a contract, but is an act of benevolence, sanctioned by the statute, and made obligatory, if in writing; yet such writing ought to pass out of the hands, and from under the control of the master. In all the cases we have had before us on this question, the certificate of the master has either been delivered to the slave, or to some third person for his benefit, and the act has thereby become consummated. But in the case before us, it must be considered as only resting in intention. No act has been done that is binding on the master. . We are of opinion, therefore, that the girl is not entitled to her freedom.

Judgment accordingly.
[Federal Register Volume 74, Number 130 (Thursday, July 9, 2009)]
[Notices]
[Pages 32960-32961]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-16295]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated June 7, 2007, and published in the Federal Register 
on June 20, 2007, 72 FR 34040, Cambrex Charles City, Inc., 1205 11th 
Street, Charles City, Iowa 50616-3466, made application by letter to 
the Drug Enforcement Administration (DEA) to be registered as an 
importer of the basic classes of controlled substances listed in 
schedule II:

------------------------------------------------------------------------
                             Drug                               Schedule
------------------------------------------------------------------------
Opium, raw (9600)............................................         II
Poppy Straw Concentrate (9670)...............................         II
------------------------------------------------------------------------

    The company plans to import the basic classes of controlled 
substances for manufacture of active pharmaceutical ingredients for 
sale to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the 
registration of Cambrex Charles City, Inc. to import the basic classes 
of controlled substances is consistent with the public interest and 
with United States obligations under international treaties, 
conventions, or protocols in effect on May 1, 1971, at this time. DEA 
has investigated Cambrex Charles City, Inc. to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic classes of controlled 
substances listed.


[[Page 32961]]


    Dated: June 24, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-16295 Filed 7-8-09; 8:45 am]
BILLING CODE 4410-09-P
<PAGE>

                                                                    EXHIBIT 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Moshe BenBassat, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual
Report of ClickSoftware Technologies Ltd. on Form 10-K for the annual period
ended December 31, 2003 fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934 and that the information contained
in such Report on Form 10-K fairly presents in all material respects the
financial condition and results of operations of ClickSoftware Technologies Ltd.
as of and for the periods presented in such Report on Form 10-K. This written
statement is being furnished to the Securities and Exchange Commission as an
exhibit accompanying such Report and shall not be deemed filed pursuant to the
Securities Exchange Act of 1934.


Dated: April 28, 2004                  By: /s/ Moshe Benbassat
                                           -------------------
                                           Moshe BenBassat
                                           Chairman and Chief Executive Officer




--------------------------------------------------------------------------------
10-K CLICKSOFTWARE TECHNOLOGIES LTD.                                    PAGE 20
```

[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4953 Introduced in House (IH)]

108th CONGRESS
  2d Session
                                H. R. 4953

        To suspend temporarily the duty on allyl ureido monomer.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             July 22, 2004

   Mr. Holt introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
        To suspend temporarily the duty on allyl ureido monomer.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ALLYL UREIDO MONOMER.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.34.41       Allyl ureido       Free         No change        No change        On or before 12/  ''.
                         monomer (CAS No.                                                   31/2007
                         90412-00-3)
                         (provided for in
                         subheading
                         2933.29.90)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
[Federal Register Volume 74, Number 135 (Thursday, July 16, 2009)]
[Notices]
[Page 34583]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-16831]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; Molecular Mechanisms of HIV 
Latency.
    Date: August 17, 2009.
    Time: 12 p.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6700B Rockledge Drive, 
Room 3133, Bethesda, MD 20817 (Telephone Conference Call).
    Contact Person: Jay Bruce Sundstrom, PhD, Scientific Review 
Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, Room 2217, 
6700B Rockledge Drive, MSC-7616, Bethesda, MD 20892-7616, 301-496-
2550, <a href="/cdn-cgi/l/email-protection#7003051e140304021f1d1a301e191119145e1e19185e171f06"><span class="__cf_email__" data-cfemail="592a2c373d2a2d2b36343319373038303d77373031773e362f">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: July 9, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-16831 Filed 7-15-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
* Pursuant to Local Rule 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in Local Rule

47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

__________________

No. 96-31163

Conference Calendar

__________________

MARY ANN LOVELL,

 Plaintiff-Appellant,

versus

DAVID NEWELL

 Defendant-Appellee.

- - - - - - - - - -

Appeal from the United States District Court

for the Eastern District of Louisiana

USDC No. 96-CV-1209-S

- - - - - - - - - 

April 16, 1997

Before REAVLEY, DAVIS, and BARKSDALE, Circuit Judges. 

PER CURIAM:*

Mary Ann Lovell appeals the district court’s dismissal

without prejudice of her complaint against David Newell for

failure to prosecute. Having sua sponte raised the issue of

jurisdiction, we AFFIRM the district court’s dismissal of the

complaint on the basis of Lovell’s failure to meet her burden of

establishing in her complaint that the district court had

jurisdiction over the matter. See Gaar v. Quirk, 86 F.3d 451,

453 (5th Cir. 1996)(sua sponte noticing jurisdictional defect);
No. 96-31163

-2-

United States v. Early, 27 F.3d 140, 142 (5th Cir.)(affirming on

the alternative basis of lack of jurisdiction), cert. denied, 115

S. Ct. 600 (1994).

 AFFIRMED.
EXHIBIT 31.1

              CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
                      SECTION 302 OF THE SARBANES-OXLEY ACT

I, Jan Aaron Sigurgeirson, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of Coastal Media Inc.;

2.   Based on my knowledge, this quarterly report does not contain any untrue
     statement of a material fact or omit to state a material fact necessary to
     make the statements made, in light of the circumstances under which such
     statements were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this quarterly report, fairly present in all
     material respects the financial condition, results of operations and cash
     flows of the registrant as of, and for, the period presented in this
     quarterly report;

4.   I am responsible for establishing and maintaining disclosure controls and
     procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
     registrant and have:

     a.   designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;
     b.   evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and
     c.   presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   I have disclosed, based on my most recent evaluation, to the registrant's
     auditors and the audit committee of registrant's board of directors (or
     persons performing the equivalent functions):

     a.   all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and
     b.   any fraud, whether or not material, that involves management or other
          employees who have a significant role in the registrant's internal
          controls; and

6.   I have indicated in this quarterly report whether or not there were
     significant changes in internal controls or in other factors that could
     significantly affect internal controls subsequent to the date of our most
     recent evaluation, including any corrective actions with regard to
     significant deficiencies and material weaknesses.

IN WITNESS WHEREOF, the undersigned has executed this certification as of the
14th day of November, 2007.


/s/ Jan Aaron Sigurgeirson
----------------------------------
Chief Executive Officer
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of China Pharma  Holdings,  Inc. a Delaware
corporation  (the  "Company") on Form  10-KSB/A for the period  ending  December
31,2005,  as filed  with the  Securities  and  Exchange  Commission  on the date
hereof(the  "Report"),  Xinhua  WU,  Chief  Financial  Officer  of the  Company,
certifies  to the best of his  knowledge,  pursuant to 18 U.S.C.  ss.  1350,  as
adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities  Exchange Act of 1934; and

(2) The  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and result of operations of the Company.

A signed  original of this  written  statement  required by Section 906 has been
provided to China Pharma  Holdings,  Inc.,  and will be retained by China Pharma
Holdings,  Inc. and furnished to the Securities  and Exchange  Commission or its
staff upon request.

 /s/ Xinhua WU
-----------------------
Xinhua WU
Chief Financial Officer
November 8, 2006
911 A.2d 64

#### STATE OF NEW JERSEY, PLAINTIFF-RESPONDENT, v. DARRYL A. HAMMARY, DEFENDANT-PETITIONER.

November 9, 2006.

ORDERED that the petition for certification is granted, limited solely to the sentencing issue raised by defendant, and the matter is summarily remanded to the trial court for resentencing in light of *State v. Natale,*184 *N.J.*458, 878 A.2d 724 (2005).
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Labor

###### Employment and Training Administration

          - [TA-W-70,439]

Pursuant to Section 223 of the Trade Act of 1974, as amended, an investigation was initiated on May 22, 2009 in response to a worker petition filed on behalf of workers of Signature Aluminum, Greenville, Pennsylvania.

The petitioning group of workers is covered by an earlier petition (TA-W-70,189) filed on May 19, 2009 that is the subject of an ongoing investigation for which a determination has not yet been issued. Consequently, further investigation in this case would serve no purpose, and the investigation under this petition has been terminated.

Signed at Washington, DC, this 9th day of June 2009.

Richard Church,

Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. E9-15749 Filed 7-2-09; 8:45 am]

BILLING CODE 4510-FN-P
Exhibit 31.1

SECTION 302 CERTIFICATION

I, William F. Rountree, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Monarch Financial Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrants other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

(b) evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to
materially affect, the registrants internal control over financial reporting; and

5. The registrants other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent
functions):

(a) all significant deficiencies in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

(b) any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.



|                     |  |                                    
|-------------------- |  | -----------------------------------
|Date: August 8, 2006 |  | /s/ William F. Rountree, Jr.       
|                     |  | William F. Rountree, Jr.,          
|                     |  | President & Chief Executive Officer



23
905 A.2d 870

#### STATE OF NEW JERSEY, PLAINTIFF-RESPONDENT, v. GREGORY CLARK, DEFENDANT-PETITIONER.

August 4, 2006.

ORDERED that the petition for certification is granted on the issue of defendant’s sentence, and the matter is summarily remanded to the trial court for resentencing in light of the Court’s decision in *State v. Pierce,*188 *N.J.*155, 902 A.2d 1195 (2006).
#### The People of the State of New York, Respondent, v Mark Cross, Appellant.

[852 NYS2d 799]

The appellant has failed to establish that he was denied the effective assistance of appellate counsel *(see Jones v Barnes,*463 US 745 [1983]; *People v Stultz,*2 NY3d 277 [2004]). Prudenti, P.J., Mastro, Rivera and Spolzino, JJ., concur.
Exhibit 32.1





CERTIFICATION


Pursuant to 18 U.S.C. 1350


(Section 906 of the Sarbanes-Oxley Act of 2002)





In connection with this Amendment No. 1 to Annual Report on Form 10-K of China Pharma Holdings, Inc. (the “Company”) for the year ended December 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Zhilin Li hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:





(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





Date: March 17, 2011
By:
/s/ Zhilin LiZhilin LiChief Executive Officer (principal executive officer)








This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.





A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.